Screener
Arbutus Biopharma Corporation ABUS Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 277,011 | 94,456 |
| Property and equipment, net of accumulated depreciation and impairment of $224 (December 31, 2025: $213) | 22 | 32 |
| Other non-current assets | 131 | 130 |
| Total assets | $277,164 | $94,618 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $4,474 | $5,459 |
| Lease liability, current | 631 | 547 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) reported total assets of $277.16M in Q1 2026.
- How has Arbutus Biopharma Corporation's total assets changed year-over-year?
- Arbutus Biopharma Corporation's total assets increased by 136.9% year-over-year, from $117.01M to $277.16M.
- What is the long-term trend for Arbutus Biopharma Corporation's total assets?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total assets has grown at a -7.1% compound annual growth rate (CAGR), from $137.08M to $94.62M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Arbutus Biopharma Corporation's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude